Une étude comparant la radiothérapie personnalisée à la radiothérapie standard chez les personnes atteintes d'un cancer de la gorge HPV-positif
Essai de phase III randomisé et en double aveugle sur la désescalade des rayonnements dans le bon risque sélectionné par FMISO PET par rapport aux rayonnements standards de soins dans le cancer de l'oropharynx positif au VPH non sélectionné
The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following:
- Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy
- How the study approaches (lower dose of radiation therapy + standard chemotherapy and standard dose of radiation therapy + standard chemotherapy) affect participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
- E-mail: leen2@mskcc.org
Sauvegarde des contacts de l'étude
- Nom: Nadeem Riaz, MD
- Numéro de téléphone: 646-888-3495
Lieux d'étude
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06102
- Recrutement
- Hartford Healthcare (Data Collection Only)
-
Contact:
- Charles Rutter, MD
- Numéro de téléphone: 860-972-2803
-
-
Florida
-
Miami, Florida, États-Unis, 33143
- Recrutement
- Baptist Alliance MCI (Data Collection Only)
-
Contact:
- Noah Kalman, MD
- Numéro de téléphone: 786-596-2000
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Recrutement
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
Middletown, New Jersey, États-Unis, 07748
- Recrutement
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
Montvale, New Jersey, États-Unis, 07645
- Recrutement
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
-
New York
-
Commack, New York, États-Unis, 11725
- Recrutement
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
Harrison, New York, États-Unis, 10604
- Recrutement
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
Uniondale, New York, États-Unis, 11553
- Recrutement
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
Contact:
- Nancy Lee, MD
- Numéro de téléphone: 212-639-3341
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of HPV associated squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or oropharyngeal walls) or squamous cell carcinoma with an unknown primary. Surgical removal of primary site is allowed.
-
Patients must test positive for both p16 expression (70% nuclear and cytoplasm expression; Ventana Medical Systems) and mRNA HPV in situ hybridization (RNAscope® 2.5 HD Reagent kit (Advanced Cell Diagnostics, Inc, Hayward, CA). Any CLIA certified testing method can be used.
-
Clinical stage Tx-2, N1-2c (AJCC, 7th ed.) without evidence of distant metastasis based on FDG PET/CT.
-
ECOG Performance Status of 0-1 or KPS >/=70
-
Age ≥ 18
-
Adequate hematologic function within 30 days prior to registration, defined as follows:
- White Blood Count (WBC) ≥ 2 K/mcL
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 10.0 g/dl
-
Adequate renal function within 30 days prior to registration, defined as follows:
o Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)
-
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
-
The patient must provide study-specific informed consent prior to study entry
-
Optional section of the protocol: Patients must be able to undergo MRI scans, i.e. not claustrophobic
Exclusion Criteria:
-
Patients with prior head and neck radiation therapy where there is >30% overlap with the current head and neck radiation fields. Exceptions can be made if determined by the PI/Co-PI that the patient can proceed with protocol activities
-
Patients whose tumors are borderline T4 based on anterior tumor extension to the extrinsic muscles of the tongue
-
Patients with simultaneous primary cancers outside of the oropharynx
o Note: Exceptions can be made for patients with simultaneous primaries outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater
o Note: Exceptions can be made for patients with prior malignancies outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities.
-
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
-
No particle therapy
-
Patients who are deemed non-compliant to all the protocol related activities
-
Contraindications to receive either cisplatin or the combination of carboplatin/5-fluorouracil at the prescribed doses.
-
Severe, active co-morbidity defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
- Hepatic Insufficiency resulting in clinical jaundice and/or coagulation defects
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personalized Chemoradiation Therapy
Patient without evidence of hypoxia will receive 30Gy in 2Gy per fraction. Concurrent chemotherapy will be given as per guidelines. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks) posttreatment standard FDG PET/CT scan will be performed and if there is persistent disease, standard neck dissection will be performed. Further standard of care will be given pending pathologic findings.1. Hypoxia negative: The entire target volume which includes GTV and CTV will receive 30Gy in 2 Gy per fraction over 15 days (PTV30). 2. Hypoxia positive (same as the standard of care): The CTV will receive 50Gy in 2Gy per fraction over 25 days. This is name PTV50 and will receive 50Gy in 2Gy per fraction over 25 days. The GTV will receive an additional boost of 20Gy in 2 Gy per fraction so that the total PTV70 dose is 70Gy. |
Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days* after start of radiation is allowed. 30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU) 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU) EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions). |
|
Comparateur actif: Standard Chemoradiation Therapy
Patient will receive 70Gy in 2Gy per fraction regardless of hypoxia status. Concurrent chemotherapy will be given as per guidelines. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks) posttreatment standard FDG PET/CT scan will be performed and if there is persistent disease, standard neck dissection will be performed. Further standard of care will be given pending pathologic findings. |
Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days* after start of radiation is allowed. 30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU) 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU) EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
overall survival
Délai: 2 years
|
The measurement of survival will be evaluated as a time from randomization to events endpoint (i.e., death due to any cause) so that censored data are allowed. To assess the overall survival rate, Kaplan-Meier estimates will be calculated and reported. |
2 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nancy Lee, MD, Memorial Sloan Kettering Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 24-200
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .